TFS Capital’s Epirus Biopharmaceuticals EPRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2015
Q4
– Sell
-80,294
Closed -$355K – 1123
2015
Q3
$355K Buy
80,294
+65,722
+451% +$386K 0.03% 624
2015
Q2
$83K Buy
14,572
+1,112
+8% +$7.59K 0.01% 824
2015
Q1
$120K Buy
+13,460
New +$108K 0.01% 858

Other funds holding EPRS

TFS Capital's EPRS Position: Q4 2015 in Review

TFS Capital sold out of Epirus Biopharmaceuticals (EPRS) in Q4 2015, closing a stake of 80,294 shares — an estimated $355K sold.

TFS Capital first reported a position in EPRS in Q1 2015 and held it in 3 quarters. The position peaked at $355K in Q3 2015. 45 funds tracked by Wall St. Rank hold EPRS as of Q4 2015.

  • TFS Capital reported no remaining Epirus Biopharmaceuticals position as of Q4 2015 after selling out during the quarter.
  • TFS Capital sold 80,294 Epirus Biopharmaceuticals shares in Q4 2015, an estimated $355K.
  • TFS Capital first reported a position in Epirus Biopharmaceuticals in Q1 2015 and held it in 3 quarters.
  • TFS Capital's Epirus Biopharmaceuticals position peaked at $355K in Q3 2015.
  • 45 funds tracked by Wall St. Rank held Epirus Biopharmaceuticals as of Q4 2015.

Based on TFS Capital's 13F filing for Q4 2015, filed 29 Jan 2016.